LEXICON PHARMACEUTICALS INC. - COMMON STOCK

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

14 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

29 May 2024 06:30:00 By Nasdaq GlobeNewswire

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

14 May 2024 06:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

09 May 2024 06:30:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

02 May 2024 15:05:00 By Nasdaq GlobeNewswire

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

29 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

29 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Host 2024 Investor Day

18 Apr 2024 07:00:40 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

03 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

25 Mar 2024 08:20:45 By Nasdaq GlobeNewswire

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

12 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update

11 Mar 2024 06:15:00 By Nasdaq GlobeNewswire

Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities

11 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA

11 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference

08 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference

21 Dec 2023 15:15:00 By Nasdaq GlobeNewswire

Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

30 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference

22 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

10 Nov 2023 15:01:00 By Nasdaq GlobeNewswire